PF 07248144
Alternative Names: PF-07248144Latest Information Update: 09 Jul 2024
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone acetyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Solid tumours
Most Recent Events
- 31 May 2024 PF 07248144 is still in phase I trials for Solid tumour (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, Combination therapy) in USA Japan, Australia, South Korea (PO, Tablet)
- 31 May 2024 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO, Tablet)